Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC lessened its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.9% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 408,793 shares of the biopharmaceutical company’s stock after selling 30,223 shares during the period. Nisa Investment Advisors LLC’s holdings in Gilead Sciences were worth $37,760,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Genesis Private Wealth LLC acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $362,000. Simon Quick Advisors LLC lifted its stake in Gilead Sciences by 24.7% during the fourth quarter. Simon Quick Advisors LLC now owns 6,120 shares of the biopharmaceutical company’s stock valued at $565,000 after buying an additional 1,214 shares in the last quarter. MCF Advisors LLC boosted its holdings in shares of Gilead Sciences by 45.2% in the fourth quarter. MCF Advisors LLC now owns 6,779 shares of the biopharmaceutical company’s stock worth $626,000 after buying an additional 2,111 shares during the period. Fort Washington Investment Advisors Inc. OH increased its position in shares of Gilead Sciences by 16.6% in the fourth quarter. Fort Washington Investment Advisors Inc. OH now owns 376,047 shares of the biopharmaceutical company’s stock worth $34,735,000 after acquiring an additional 53,617 shares in the last quarter. Finally, Atomi Financial Group Inc. raised its holdings in shares of Gilead Sciences by 36.7% during the fourth quarter. Atomi Financial Group Inc. now owns 8,312 shares of the biopharmaceutical company’s stock valued at $768,000 after acquiring an additional 2,231 shares during the period. 83.67% of the stock is owned by institutional investors.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 6,788 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the completion of the sale, the director now owns 8,920 shares in the company, valued at approximately $815,198.80. This trade represents a 43.21 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the sale, the chief financial officer now directly owns 129,873 shares in the company, valued at $11,863,898.55. The trade was a 1.89 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 456,234 shares of company stock worth $42,130,461. Insiders own 0.29% of the company’s stock.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $92.96 on Wednesday. The firm has a market capitalization of $115.85 billion, a PE ratio of 1,032.89, a PEG ratio of 1.29 and a beta of 0.18. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $98.90. The firm’s fifty day simple moving average is $91.65 and its 200 day simple moving average is $84.38.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. During the same period in the previous year, the company posted $2.29 earnings per share. The firm’s revenue for the quarter was up 7.0% on a year-over-year basis. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post 4.36 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were given a $0.77 dividend. The ex-dividend date was Friday, December 13th. This represents a $3.08 annualized dividend and a dividend yield of 3.31%. Gilead Sciences’s dividend payout ratio is 3,422.22%.

Analyst Upgrades and Downgrades

Several research firms have weighed in on GILD. Morgan Stanley upgraded shares of Gilead Sciences from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $87.00 to $113.00 in a research report on Friday, January 10th. Leerink Partnrs upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Monday, October 21st. Wells Fargo & Company increased their price objective on Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Wolfe Research initiated coverage on Gilead Sciences in a research note on Friday, November 15th. They set an “outperform” rating and a $110.00 target price on the stock. Finally, Truist Financial increased their price target on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a research report on Friday, November 8th. Eleven investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average target price of $97.96.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.